Top Story
- Health Policy
The U.S. Food and Drug Administration (FDA) recently approved Winrevair, a new treatment developed by pharmaceutical giant Merck for adults suffering from pulmonary arterial hypertension (PAH). This approval introduces a novel therapy option for the estimated 40,000 PAH patients in the U.S., aiming to significantly impact [...]
Latest Stories
- Patient Outcomes & Engagement
Featured Webinars
Beyond Accelerated Approvals: External Control Arms
Wednesday, April 10, 2024
Sponsor: Cardinal Health
Delphi Panels: What Are They Good For?
Tuesday, March 12, 2024
Sponsor: Partnership for Health Analytic Research (PHAR)
Patient Voices Matter: Transforming Industry-Sponsored Real-World Evidence with Patient-Centric Approaches
Thursday, February 29, 2024
Sponsor: Carelon Research
Integrated Evidence Generation Planning: Driving Successful Reimbursement and Life Cycle Management
Tuesday, February 27, 2024
Sponsor: OPEN Health
Handpicked Promotions & Highlights
Latest in Catalyst News powered by BioPharmCatalyst
Reviva Pharmaceuticals Holdings RVPH date announcement
Now that the Phase 3 trial of Brilaroxazine - (RECOVER) is completed, Reviva Pharmaceuticals Holdings will announce their top-line results on December 31, 2024. As of now, the drug has a 60.5% chance of moving [...]
Read MoreAvalo Therapeutics MIST date announcement
Milestone Pharmaceuticals has an announcement scheduled for June 30, 2024 regarding their recent NDA Filing trial of Etripamil - (RAPID). The community is currently bullish on the prospects of progression, as all four community members [...]
Read MoreAtara Biotherapeutics ATRA earnings announcement
Atara Biotherapeutics revealed their most recent quarterly earnings data, in which both revenue and EPS ended up lower than estimates. EPS was estimated to be -$0.48, but the actual figure came in at -$0.56.
Read MoreCandel Therapeutics CADL earnings announcement
Candel Therapeutics revealed their most recent quarterly earnings data, in which both revenue and EPS ended up lower than estimates. EPS, at -$0.38, was the biggest surprise for the quarter, as it missed [...]
Read MoreSearch HealthEconomics.com
Throw in a keyword, research topic, disease model or technology of interest